ライフサイエンスコーパス: bone disorder

1 ntributes to post-transplant CKD mineral and bone disorder.

2 n cherubism, a rare autosomal-dominant human bone disorder.

3 play a pivotal role in diagnosing metabolic bone disorders.

4 could lead to new treatments for age-related bone disorders.

5 jor drug target for osteoporosis and related-bone disorders.

6 es with risks for cancer, cardiovascular and bone disorders.

7 with great promise as therapeutic agents for bone disorders.

8 rs was an independent factor associated with bone disorders.

9 t role in the treatment of periodontitis and bone disorders.

10 ts further our knowledge of FGFR3-associated bone disorders.

11 al benefit and render BMT more applicable to bone disorders.

12 te human Opt as a candidate gene for brittle bone disorders.

13 therapeutic target for bone loss in various bone disorders.

14 d paralog of MAN1, an NE component linked to bone disorders.

15 ention, and treatment of pediatric metabolic bone disorders.

16 ct of mechanism-based anabolic therapies for bone disorders.

17 immunologic aspects of the autoinflammatory bone disorders.

18 ht yield novel therapeutics to treat typical bone disorders.

19 r bone remodeling and is altered in multiple bone disorders.

20 ions in CBF genes are found in leukemias and bone disorders.

21 , raising new directions in the treatment of bone disorders.

22 An adynamic bone disorder (ABD) is an important complication of chro

23 n the Runt domain found in hematopoietic and bone disorders affect its affinity for DNA.

24 rteriosclerosis, vascular calcification, and bone disorders, all of which are also associated with ag

25 tudy revealed a high prevalence of metabolic bone disorders among viral cirrhotic patients.

26 phosphatemia in a mouse model of CKD-mineral bone disorder and alphaKL-null mice.

27 sk factor for periodontitis, an inflammatory bone disorder and the greatest cause of tooth loss in ad

28 d Amy, analogs of which are therapeutics for bone disorders and diabetes, respectively.

29 Systemic bone disorders and PAD are frequent in ESRD.

30 phosphatemia in a mouse model of CKD-mineral bone disorder, and it reduced hyperphosphatemia and prev

31 tations in CBF genes are found in leukemias, bone disorders, and gastric cancer.

32 tations in CBF genes are found in leukemias, bone disorders, and gastric cancers.

33 nfections, vitamin D deficiency or metabolic bone disorders, anxiety disorders, and fractures; the in

34 Finally, several cartilage and bone disorders are due to abnormalities in sulfate trans

35 Bone disorders are of significant concern due to increas

36 Metabolic Bone disorders are well-recognized extrahepatic complica

37 Findings from research into mineral bone disorder associated with CKD (CKD-MBD) could help t

38 Osteoporosis is a metabolic bone disorder associated with compromised bone strength

39 -Engelmann disease, a nonmalignant metabolic bone disorder associated with increased TGF-beta activit

40 Osteoporosis is a bone disorder associated with loss of bone mineral densi

41 sents a summary of recent reports concerning bone disorders associated with disorders of the liver an

42 del, however, is complicated by the adynamic bone disorder; both calcitriol and paricalcitol stimulat

43 hosphonates (NBPs) are taken by millions for bone disorders but may cause serious inflammatory reacti

44 he pathophysiology of many acute and chronic bone disorders, but the specific inflammatory networks t

45 e bone disease' has mainly been considered a bone disorder caused by collagen mutations.

46 reatment of craniosynostosis or other severe bone disorders caused by mutations in FGFRs that current

47 tegies and may inform clinical treatments of bone disorders causes by load-deficiency.

48 esis imperfecta (OI) is an inherited brittle bone disorder characterized by bone fragility and low bo

49 O, MIM 174810) is a rare, autosomal dominant bone disorder characterized by focal areas of increased

50 sease of bone, or "osteitis deformans," is a bone disorder characterized by rapid bone remodeling res

51 Osteopetrosis is a heterogeneous group of bone disorders characterized by the failure of osteoclas

52 Chronic kidney disease-mineral and bone disorder (CKD-MBD) is associated with secondary hyp

53 r risk and are components of CKD-mineral and bone disorder (CKD-MBD).

54 er small molecule leads for the treatment of bone disorders concluded with the discovery of a compoun

55 cancer diagnosis, cancer margin evaluation, bone disorder detection and glucose level determination.

56 anifestations of NF1, including learning and bone disorders emphasize the importance of dissecting th

57 Another bone disorder, familial expansile osteolysis (FEO), alth

58 CKD in this model is associated the adynamic bone disorder form of renal osteodystrophy.

59 gement of chronic kidney disease-mineral and bone disorders has recently changed.

60 en learned in the monogenic autoinflammatory bone disorders, IL-1 is emerging as an important pathway

61 es, which lead to the development of various bone disorders in both women and men.

62 cs and immunologic basis of autoinflammatory bone disorders including chronic recurrent multifocal os

63 TNF inhibits bone formation in inflammatory bone disorders is by promoting Runx2 proteasomal degrada

64 The chronic kidney disease (CKD)-mineral bone disorder (MBD) is a syndrome recently coined to emb

65 Anemia and mineral and bone disorders (MBD) are both important and common compl

66 There are two primary types of bone disorders observed in patients with end-stage renal

67 e expression to osteoblasts for treatment of bone disorders or tumor metastasis to the skeleton.

68 ), certain types of cancer, and degenerative bone disorders (osteoarthritis).

69 ollagen triple helix, lead to the hereditary bone disorder osteogenesis imperfecta (OI).

70 The hereditary bone disorder osteogenesis imperfecta is often caused by

71 es in MSCs from individuals with the brittle bone disorder osteogenesis imperfecta, demonstrating suc

72 ple helix results in the dominant hereditary bone disorder osteogenesis imperfecta.

73 wing prevalence of metabolic and age-related bone disorders, our results demonstrate for the first ti

74 Human genetic bone disorders provide insight into bone regulatory proc

75 flammatory networks that regulate individual bone disorders remain to be elucidated.

76 sent the first five cases of a new recessive bone disorder resulting from null LEPRE1 alleles; its ph

77 ures, gene identification in each 'vanishing bone' disorder should provide unique insights into genet

78 s an established concept in the treatment of bone disorders such as osteoporosis or certain forms of

79 are potential therapies for the treatment of bone disorders such as osteoporosis.

80 process, and deregulation can lead to severe bone disorders such as osteoporosis.

81 represent potential therapeutic targets for bone disorders such as osteoporosis.

82 l, bone anabolic agents for the treatment of bone disorders such as osteoporosis.

83 ediator of joint destruction in inflammatory bone disorders, such as RA.

84 Cherubism is a rare autoinflammatory bone disorder that is associated with point mutations in

85 een identified in monogenic autoinflammatory bone disorders that have allowed more detailed dissectio

86 Newly diagnosed metabolic bone disorders were seen in 58% of the breast cancer pop

87 Bone disorders were significantly more frequent in old p

88 ations of chronic kidney disease-mineral and bone disorder with a special focus on the incidence of f

89 e P392L SQSTM1 mutation in humans, develop a bone disorder with remarkable similarity to PDB.

90 ssure index (ABix) and evaluated mineral and bone disorders with bone histomorphometry.